

## News Release

### Launch of Lonza's Phosphatidylserine Brand Memree™

Basel, Switzerland, 17 April 2012 – Today Lonza announced the launch of the Memree™ line of products containing high quality, soy-based phosphatidylserine. The Memree™ brand includes MemreePS™ and MemreePlus™, a patented combination of phosphatidylserine and phosphatidic acid.

As announced in October 2011, Lonza has entered into an exclusive collaboration with Lipogen Ltd and received the global rights to commercialize this line of products in dietary supplements, medical foods, and food and beverage applications. Both MemreePS™ and MemreePlus™ are positioned for cognitive health applications, whereas MemreePlus™ has additionally been shown to reduce cortisol levels. Cortisol is a hormone that is associated with stress as well as impeded recovery after exercise. The Memree™ products are available both in liquid and dry forms.

To learn more about Memree™ please visit [www.memree-ps.com](http://www.memree-ps.com).

#### About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza is not subject to the SGX-ST's continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2011, the company had sales of CHF 2.692 billion. Further information can be found at [www.lonza.com](http://www.lonza.com).

Nutrition

**Lonza**

Lonza Group Ltd  
Muenchensteinerstrasse 38  
4002 Basel, Switzerland  
[www.lonza.com](http://www.lonza.com)

## News Release

### Further Information

Lonza Group Ltd  
Head of Corporate Communications  
Dominik Werner  
Tel +41 61 316 8798  
Fax +41 61 316 9798  
[dominik.werner@lonza.com](mailto:dominik.werner@lonza.com)

Lonza Group Ltd  
Investor Relations  
Dirk Oehlers  
Tel +41 61 316 8540  
Fax +41 61 316 9540  
[dirk.oehlers@lonza.com](mailto:dirk.oehlers@lonza.com)

Lonza Group Ltd  
Media Relations  
Melanie Disa  
Tel +12013169413  
Fax +1 201 696 3533  
[melanie.disa@lonza.com](mailto:melanie.disa@lonza.com)